NVG-291 is a first- and potentially best-in-class neuroreparative peptide currently being evaluated in the Phase 1b/2a CONNECT SCI Study (NCT05965700) of individuals with cervical motor incomplete spinal cord injury: chronic (1-10 years post-injury) and subacute (20-90 days post-injury). NVG-291 is administered as a daily subcutaneous injection under the skin for 12 weeks.
NVG-291 is actively being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with cervical motor incomplete spinal cord injury.
The chronic cohort (1-10 years post-injury) of the CONNECT SCI Study is completed and the expanded results can be seen here. The subacute cohort for individuals between
20- and 90-days post-injury is active and enrollment is ongoing.
NervGen has initiated an Expanded Access Policy to allow treatment use of NVG-291 for those individuals with spinal cord injury who have participated in the chronic cohort of the Phase 1b/2a CONNECT SCI Study and meet specific eligibility criteria. Click here for further information on Expanded Access to NVG-291.
It is generally best to start your search for a clinical trial by speaking with your treating physician. Talk to them about any trials that might be right for your condition. As they may not be aware of all available trials, you can also search for trials online at www.clinicaltrials.gov, https://health-products.canada.ca/, www.anzctr.org.au, or https://eudract.ema.europa.eu/, which are searchable databases of clinical trials done in various parts of the world. Any clinical trials conducted by NervGen will be listed on one or more of these websites.
NervGen Pharma Corp (“NervGen”) (NASDAQ: NGEN), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. NervGen’s lead therapeutic candidate, NVG-291, is a first- and potentially best-in-class subcutaneously administered candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: [email protected]